New hope for mysterious skin rash: dupilumab shows promise
NCT ID NCT06012448
First seen Jan 12, 2026 · Last updated May 02, 2026 · Updated 18 times
Summary
This study tested the drug dupilumab in 10 adults with a chronic, moderate-to-severe skin condition called dermal hypersensitivity reaction. The goal was to see if dupilumab is safe and how it affects immune cells in the skin. Researchers measured changes in skin area affected and immune cell levels over 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMAL HYPERSENSITIVITY REACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.